RT Journal Article
SR Electronic
T1 Anemia of chronic kidney disease: Will new agents deliver on their promise?
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 212
OP 222
DO 10.3949/ccjm.89a.21100
VO 89
IS 4
A1 Tarek Souaid
A1 Jonathan Taliercio
A1 James F. Simon
A1 Ali Mehdi
A1 Georges N. Nakhoul
YR 2022
UL http://www.ccjm.org/content/89/4/212.abstract
AB Anemia is a well-known complication of chronic kidney disease, and its treatment remains a challenge. Although erythropoiesis-stimulating agents (ESAs) raise hemoglobin levels, their benefits appear to be limited to decreasing the number of blood transfusions needed and perhaps improving quality of life. The newly developed prolyl hydroxylase inhibitors (PHIs)—agents that increase endogenous erythropoietin production—promise to improve outcomes for patients with anemia of chronic kidney disease. Randomized controlled trials have found these drugs to be at least as effective as ESAs, and the drugs are used in other countries. However, PHIs have yet to be approved in the United States.